KR101793777B1 - 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 피라졸 유도체의 용도 - Google Patents

만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 피라졸 유도체의 용도 Download PDF

Info

Publication number
KR101793777B1
KR101793777B1 KR1020147025904A KR20147025904A KR101793777B1 KR 101793777 B1 KR101793777 B1 KR 101793777B1 KR 1020147025904 A KR1020147025904 A KR 1020147025904A KR 20147025904 A KR20147025904 A KR 20147025904A KR 101793777 B1 KR101793777 B1 KR 101793777B1
Authority
KR
South Korea
Prior art keywords
treatment
pharmaceutically acceptable
pyrazol
amino
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147025904A
Other languages
English (en)
Korean (ko)
Other versions
KR20140146073A (ko
Inventor
폴 앤드류 포드
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20140146073A publication Critical patent/KR20140146073A/ko
Application granted granted Critical
Publication of KR101793777B1 publication Critical patent/KR101793777B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020147025904A 2012-03-20 2013-03-19 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 피라졸 유도체의 용도 Active KR101793777B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613187P 2012-03-20 2012-03-20
US61/613,187 2012-03-20
PCT/EP2013/055730 WO2013139809A1 (en) 2012-03-20 2013-03-19 Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Publications (2)

Publication Number Publication Date
KR20140146073A KR20140146073A (ko) 2014-12-24
KR101793777B1 true KR101793777B1 (ko) 2017-11-03

Family

ID=47901996

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147025904A Active KR101793777B1 (ko) 2012-03-20 2013-03-19 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 피라졸 유도체의 용도

Country Status (29)

Country Link
US (2) US9339491B2 (enExample)
EP (1) EP2827860B1 (enExample)
JP (1) JP6091593B2 (enExample)
KR (1) KR101793777B1 (enExample)
CN (1) CN104203234B (enExample)
AU (1) AU2013237503B2 (enExample)
BR (1) BR112014023107B1 (enExample)
CA (1) CA2866108C (enExample)
CL (1) CL2014002471A1 (enExample)
CY (1) CY1118327T1 (enExample)
DK (1) DK2827860T3 (enExample)
ES (1) ES2605942T3 (enExample)
HR (1) HRP20161514T1 (enExample)
HU (1) HUE032004T2 (enExample)
IL (1) IL234537A (enExample)
LT (1) LT2827860T (enExample)
MA (1) MA37455B1 (enExample)
MX (1) MX351996B (enExample)
NZ (1) NZ628392A (enExample)
PH (1) PH12014502107B1 (enExample)
PL (1) PL2827860T3 (enExample)
PT (1) PT2827860T (enExample)
RU (1) RU2625762C2 (enExample)
SG (1) SG11201404941WA (enExample)
SI (1) SI2827860T1 (enExample)
TN (1) TN2014000350A1 (enExample)
TW (1) TWI583381B (enExample)
WO (1) WO2013139809A1 (enExample)
ZA (1) ZA201405871B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2600833C1 (ru) * 2015-09-03 2016-10-27 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) Способ лечения хронической обструктивной болезни легких
RU2600822C1 (ru) * 2015-09-03 2016-10-27 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ (ФГБУ "РНЦРХТ" Минздрава России) Способ лечения хронического обструктивного бронхита
WO2017153702A1 (en) 2016-03-08 2017-09-14 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
AU2016397046B2 (en) * 2016-03-08 2022-05-12 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
US10331542B2 (en) * 2016-06-23 2019-06-25 International Business Machines Corporation System and method for detecting and alerting unexpected behavior of software applications
GB201612238D0 (en) * 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
GB201612240D0 (en) * 2016-07-14 2016-08-31 Mereo Biopharma 1 Ltd Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3692144A1 (en) 2017-10-05 2020-08-12 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
PT3585382T (pt) * 2017-12-11 2021-08-19 Mereo Biopharma 1 Ltd Utilização de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-n-ciclopropil-4-metilbenzamida no tratamento de exacerbações agudas da doença pulmonar obstrutiva crónica
KR102760007B1 (ko) * 2017-12-11 2025-02-03 메레오 바이오파마 1 리미티드 만성 폐쇄성 폐 질환의 급성 악화의 예방 또는 감소에서의 3-[5-아미노-4-(3-시아노벤조일)-피라졸-1-일]-n-시클로프로필-4-메틸벤즈아미드의 용도
CN114141383A (zh) * 2021-12-17 2022-03-04 湖南大学 慢阻肺智能护理方法、装置及系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009973A1 (en) * 2003-06-26 2005-02-03 Novartis Ag 5-membered heterocycle-based p38 kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603684D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009973A1 (en) * 2003-06-26 2005-02-03 Novartis Ag 5-membered heterocycle-based p38 kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEST, 2011, vol. 139, No. 6, p. 1470-1479

Also Published As

Publication number Publication date
HUE032004T2 (en) 2017-08-28
NZ628392A (en) 2016-06-24
BR112014023107B1 (pt) 2021-08-10
CN104203234B (zh) 2017-06-13
TW201343162A (zh) 2013-11-01
CN104203234A (zh) 2014-12-10
RU2625762C2 (ru) 2017-07-18
HRP20161514T1 (hr) 2016-12-30
JP6091593B2 (ja) 2017-03-08
TWI583381B (zh) 2017-05-21
EP2827860A1 (en) 2015-01-28
CL2014002471A1 (es) 2015-01-09
MA37455B1 (fr) 2017-03-31
JP2015510916A (ja) 2015-04-13
CA2866108A1 (en) 2013-09-26
KR20140146073A (ko) 2014-12-24
US20160243081A1 (en) 2016-08-25
CA2866108C (en) 2017-03-07
RU2014141893A (ru) 2016-05-10
WO2013139809A1 (en) 2013-09-26
LT2827860T (lt) 2016-12-12
HK1200352A1 (en) 2015-08-07
BR112014023107A2 (enExample) 2017-06-20
ES2605942T3 (es) 2017-03-17
DK2827860T3 (en) 2016-12-12
AU2013237503B2 (en) 2016-05-26
TN2014000350A1 (en) 2015-12-21
SI2827860T1 (sl) 2017-01-31
MX351996B (es) 2017-11-06
PL2827860T3 (pl) 2017-09-29
PT2827860T (pt) 2016-12-20
CY1118327T1 (el) 2017-06-28
MX2014011291A (es) 2014-10-13
SG11201404941WA (en) 2014-10-30
MA37455A1 (fr) 2016-08-31
US9339491B2 (en) 2016-05-17
US20150031736A1 (en) 2015-01-29
PH12014502107B1 (en) 2019-11-27
AU2013237503A1 (en) 2014-09-25
PH12014502107A1 (en) 2014-12-10
ZA201405871B (en) 2016-01-27
EP2827860B1 (en) 2016-10-26
IL234537A (en) 2016-09-29

Similar Documents

Publication Publication Date Title
KR101793777B1 (ko) 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 피라졸 유도체의 용도
JP2505944B2 (ja) （Ｓ）―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
JP2020514318A5 (enExample)
JP2013536825A (ja) ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
KR20150046110A (ko) 피르페니돈 치료제의 투여 방법
JP2017537129A (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
CN115515590A (zh) 马赛替尼用于治疗多发性硬化患者亚群
ES3006014T3 (en) Use of nalfurafine for the treatment of demyelinating diseases
JPH0320222A (ja) 脳内虚血症治療剤
CA3026770C (en) Andrographolide treats progressive forms of multiple sclerosis
JP2021075470A (ja) 肺線維症の予防または治療のための医薬
KR20170118830A (ko) 조현병의 치료를 위한 일로페리돈
Singh et al. A phase I, randomised, double blind, placebo controlled, study to assess the safety, tolerability and pharmacokinetics of multiple inhaled doses of RPL554 administered by nebuliser to healthy male subjects and stable COPD patients
EP3831384A1 (en) Use of masitinib for the treatment of eosinophilic asthma
JP6734470B2 (ja) ヒスタミン−３受容体インバースアゴニストとアセチルコリンエステラーゼ阻害剤との組合せ
HK1200352B (en) Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
JP6188784B2 (ja) 炎症性および免疫性疾患の治療のための組成物
WO2025250560A1 (en) Methods for treating bronchiectasis
CN120899911A (zh) JAK抑制剂或Janus激酶蛋白降解剂治疗纤维化的用途和方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9